Save Product
Product Details
Specificity
This product is a specific antibody specifically reacts with DM-1&DM-4.
Source
Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 is a Mouse monoclonal antibody produced from a hybridoma created by fusing SP2/0 myeloma and Mouse B-lymphocytes.
Isotype
Mouse IgG1 | Mouse Kappa
Conjugate
Unconjugated
Reactivity
Chemical
Immunogen
DM-1
Application
ApplicationRecommended UsageELISA0.4-200 ng/mLPurification
Protein A purified / Protein G purified
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-ELISA
Immobilized Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) at 5 μg/mL, add Trastuzumab-DM1 in the 50% Human serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (QC tested).
Protocol
Immobilized ADC-DM4 at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) with a linear range of 0.20-6.25ng/mL (Routinely tested).
Protocol
Immobilized Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) at 2 μg/mL, add increasing concentrations of Trastuzumab-DM1 (T-DM1), and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 8 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 0.5 ng/mL (Routinely tested).
Protocol
Serial dilutions of DM1 were added into Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73): Trastuzumab-DM1 binding reactions. The half maximal inhibitory concentration (IC50) is 0.148 μg/mL (Routinely tested).
Protocol
Cross Verification
ELISA binding of Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) with Trastuzumab Deruxtecan, Sacituzumab Govitecam, Disitamab Vedotin (RC48), Trastuzumab MMAE and Trastuzumab-DM1 conjugated antibody respectively.
The coating antibody was Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73), used at 1 μg/mL concentration. The primary antibody were different payload conjugated antibodies, including Trastuzumab Deruxtecan, Sacituzumab Govitecam, Disitamab Vedotin (RC48), Trastuzumab MMAE and Trastuzumab-DM1 conjugated antibodies used at 0.5 μg/mL concentration. The secondary antibody was Peroxidase AffiniPure Goat Anti-Human IgG, Fcγ fragment specific (min X Bov, Hrs, Ms Sr Prot) (Jackson, Cat. No. 109-035-098) used at 1:12000 concentration.
Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) is specific to Trastuzumab-DM1 and has no cross-reactivity with Trastuzumab Deruxtecan, Disitamab Vedotin (RC48), Trastuzumab MMAE and Sacituzumab Govitecam (Routinely tested).
Customer Reviews Writing Reviews
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing